Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: The insulin-changing study intending to gain patients’ insights into insulin treatment with patient-reported health outcomes in actual clinical treatments (INSIGHTs) study

Hitoshi Ishii1, Yasuo Terauchi2, Hideaki Jinnouchi3, Masanori Taketsuna4, Masakazu Takeuchi4*, Takeshi Imaoka4

ABSTRACT
Aims/Introduction: Our primary objective was to assess changes in quality of life (QOL) associated with changes in insulin regimen in patients with type 2 diabetes mellitus. Secondary objectives were to assess the reasons for and patterns of changes in insulin regimen, and the effects on glycemic control.

Materials and Methods: This 12-week, observational study included patients with type 2 diabetes mellitus (n = 625) who planned to change insulin regimen (type of insulin, injection device and/or number of injections). The primary outcome measure was a change from baseline in QOL assessed by the Insulin Therapy-Related (ITR) QOL questionnaire. The secondary outcome measures included change from baseline in plasma glycated hemoglobin (HbA1c) level, the reasons for and pattern of insulin regimen change, and change from baseline in QOL assessed by Diabetes Treatment Satisfaction Questionnaire (DTSQ).

Results: QOL did not worsen during the study. Improvements were seen in the ITR-QOL ‘daily activities’ subscale score (baseline: 12.7 ± 2.3; week 12: 12.9 ± 2.3; P = 0.038, n = 568) and the DTSQ ‘perceived frequency of hyperglycemia’ subscale score (baseline: 3.4 ± 1.6; week 12: 3.0 ± 1.7; P < 0.001, n = 573). Glycemic control improved, as evidenced by decreased plasma HbA1c levels (baseline: 8.21 ± 1.47%; week 12: 7.85 ± 1.31%; P < 0.001, n = 606).

Conclusions: It was suggested that insulin regimen changes might improve glycemic control in Japanese patients with type 2 diabetes mellitus without worsening QOL. This trial was registered with ClinicalTrials.gov (no. NCT01055808). (J Diabetes Invest, doi: 10.1111/jdi.12086, 2013)

KEY WORDS: Glycated hemoglobin, Insulin therapy-related quality of life questionnaire, Type 2 diabetes mellitus

INTRODUCTION
Maintaining glycemic control is the primary goal of treatment for type 2 diabetes mellitus. Several landmark studies, including the Japanese Kumamoto study1,2 and the United Kingdom Prospective Diabetes Study3,4, have shown that good glycemic control using intensive insulin therapy reduces the risk of microvascular complications, and might also reduce the risk of macrovascular complications in patients with type 2 diabetes mellitus. Intensification of insulin therapy is often necessary to maintain glycemic control in patients as the disease progresses. Intensification might include switching to or adding another type of insulin and/or increasing the number of injections per day. The recent expansion of available insulin preparations allows insulin therapy to be tailored to individual patients’ clinical needs and personal preferences. In Japan, the rapid-acting analogs, insulin lispro and insulin aspart, became available in 2001, and premixed combinations of each analog in 2003. The long-acting preparations, insulin glargine and insulin detemir, became available in 2003 and 2007, respectively.

Insulin therapy can have both positive and negative impacts on quality of life (QOL). Insulin therapy generally provides better glycemic control and improves health-related QOL by
reducing diabetic complications\textsuperscript{5–7}. However, insulin therapy can be inconvenient, painful and burdensome, and can restrict patients’ daily activities\textsuperscript{8}. Furthermore, insulin treatment sometimes induces hypoglycemic episodes, which detract from QOL, both in terms of the actual events and the fear they cause. A number of studies have compared the effects of specific insulin types and regimens on QOL in patients with type 2 diabetes mellitus\textsuperscript{9–16}. Most of these studies focused on insulin initiation or the comparison between insulin therapies, such as regular insulin vs rapid-acting insulin analogs\textsuperscript{9,11,12}, neutral protamine Hagedorn (NPH) vs long-acting insulin analogs\textsuperscript{9,10,12}, or multiple daily injections vs continuous subcutaneous insulin infusion (CSII)\textsuperscript{16}. In contrast, few observational studies have examined the effects of changes in insulin regimen on QOL when intensifying insulin therapy in clinical practice.

The primary objective of this multicenter, observational study was to assess the changes in QOL associated with changes in insulin regimen in Japanese patients with type 2 diabetes mellitus. The secondary objectives were to assess the reasons for changing insulin regimen, the pattern of these changes and the effects on glycemic control as measured by plasma glycated hemoglobin (HbA\textsubscript{1c}) levels.

MATERIALS AND METHODS

Study Design

The INSulin-changing study Intending to Gain patients’ insights into insulin treatment with patient-reported Health outcomes in actual clinical Treatments (INSIGHTs) study was a 12-week, prospective, non-controlled observational study carried out between January and November 2010 at 68 hospital departments (including departments of endocrinology and metabolism, diabetes, and general internal medicine) in Japan. Patients with type 2 diabetes mellitus who were being treated with insulin and planned to change therapy were assessed for 12 weeks after the change in therapy (baseline). The outcomes assessed before and/or after the change in therapy included QOL, plasma levels of HbA\textsubscript{1c}, reasons for the change in therapy, patterns of changes in therapy, treatment adherence and satisfaction, and concomitant oral antidiabetic medication.

The study was carried out in accordance with the Declaration of Helsinki and Good Post–Marketing Study Practice (based on the International Conference for Harmonization Good Clinical Practice) in Japan\textsuperscript{19}, and in accordance with the local ethical requirements at each site. Written informed consent was obtained from all patients before any study-specific procedures were carried out. This trial was registered with ClinicalTrials.gov (no. NCT01055808).

Study Population

Patients with type 2 diabetes mellitus aged \(\geq 20\) years who planned to change one or more aspect of their insulin regimen (type of insulin, injecting device and/or number of injections per day) during the registration period were eligible to enter the study. Patients must have been receiving the same insulin regimen for at least 3 months before entering. Switching insulin preparation within the same class (e.g. insulin lispro to insulin aspart) was not considered a change in insulin regimen.

Patients were excluded from participation if they planned to discontinue insulin therapy, had used or planned to use continuous subcutaneous insulin infusion, had type 1 diabetes mellitus, had obviously poor treatment adherence (determined by the investigator and based on patient history) or were incapable of completing the study questionnaires.

Insulin Treatment Regimen During the Study

Patients’ individual insulin regimens during the study were determined by their treating doctors, and each insulin preparation was to be administered according to the recommended dose and frequency. The study sponsor did not provide any incentive for doctors to prescribe specific products, although individual doctors might have had personal preferences or biases. After patients changed the type of insulin, injecting device and/or number of injections per day, they could not change their insulin regimen during the study. Insulin dose adjustments, however, were allowed.

Outcome Measures

Primary Outcome Measure

The primary outcome measure was the change from baseline in Insulin Therapy-Related Quality of Life (ITR-QOL) scores\textsuperscript{17,18}. The ITR-QOL questionnaire is a patient-reported set of 23 questions relating to the impact of insulin therapy on aspects of daily life. Each question is rated on a five-point scale, with higher scores indicating a better QOL. The ITR-QOL consists of four subscales: social activities (five questions), physical functioning (four questions), daily activities (three questions) and feelings about insulin treatment (11 questions). The ITR-QOL questionnaire was completed at baseline and at week 12 (or discontinuation).

Secondary Outcome Measures

Change from Baseline in Plasma HbA\textsubscript{1c}

Baseline plasma HbA\textsubscript{1c} levels were determined within 4 weeks before or 5 days after baseline. End-of-study plasma HbA\textsubscript{1c} levels were determined within 2 weeks of week 12 (i.e. between week 10 and week 14) or discontinuation. Plasma HbA\textsubscript{1c} levels were measured at local laboratories using standard methods, and are expressed as National Glycohemoglobin Standardization Program equivalent values (i.e. the Japan Diabetes Society HbA\textsubscript{1c} value +0.4\%\textsuperscript{20,21}).

Reasons for Change in Insulin Regimen

At baseline, both patients and doctors chose one or more from a list of reasons (Table 2) for the change (including ‘Other’).

Pattern of Changes in Insulin Regimen

The details of each patient’s insulin regimen were recorded before the regimen was changed, at baseline and at week 12.
(or discontinuation). These details included the category of insulin: (i) rapid-acting (rapid- or ultra-rapid-acting); (ii) biphasic (biphasic/premixed); (iii) long-acting (intermediate- or long-acting/basal); (iv) the type of insulin preparation (e.g., human insulin or insulin analog); (v) the number of injections per day; (vi) the time(s) of injection (before breakfast, before lunch, before dinner, bedtime); (vii) the type of injecting device (disposable, cartridge, syringe); and (viii) the total insulin dose per day.

Treatment Adherence
Patients completed a treatment adherence questionnaire, in which they reported the extent of adherence (always, often, usually, occasionally, not at all) for each injection time, at baseline and at week 12 (or discontinuation).

Concomitant Oral Antidiabetic Medication
All concomitant oral antidiabetic medications were recorded at baseline and at week 12 (or discontinuation).

Change From Baseline in Diabetes Treatment Satisfaction Questionnaire Score
The Diabetes Treatment Satisfaction Questionnaire (DTSQ) is a patient-reported assessment of treatment satisfaction (six questions) and perceived frequency of severe hypoglycemia and hyperglycemia (two questions)22. Each question is rated on a six-point scale, with higher scores indicating either greater treatment satisfaction or greater perceived frequency of hypoglycemic or hyperglycemic events. Patients completed a Japanese version of the DTSQ23 at baseline and at week 12 (or discontinuation).

Questionnaire Procedures
Patients normally completed all questionnaires at the study site, but not in the presence of their doctors. All completed questionnaires (both patient and doctor) were sealed and submitted according to each institution’s procedures.

Statistical Analysis
The standard deviation (SD) of the change in the total ITR-QOL score was assumed to be 12.0, based on previous results17. To estimate the change from baseline in the ITR-QOL total score with sufficient precision (95% confidence interval for the estimated mean change with a width of 2.0), 554 patients were required. Allowing for 20% dropout, the study aimed to include approximately 700 patients.

Summary statistics (mean, SD) were calculated for all continuous variables (e.g., age, weight, ITR-QOL scores, HbA1c levels). A one-sample $t$-test was used to compare baseline and week 12 values within patient subgroups, and a two-sample $t$-test was used to compare changes from baseline between patient subgroups. A multiple linear regression model was used to assess the relationship between independent variables (age, sex, body mass index, baseline HbA1c level, duration of diabetes, number

---

**Figure 1** | Patient disposition, including number of patients with end-of-study primary outcome (ITR-QOL) data. *Includes two patients with both a change in insulin regimen plus another reason for discontinuation.
of insulin injections, type of insulin and device) and the change from baseline in plasma HbA1c level. A backward, step-down method was used to further assess variables with \( P < 0.05 \) in the full regression model. Missing data were not imputed. All statistical analyses were carried out using SAS® version 9.1.3 (SAS, Cary, NC, USA), and \( P \)-values \( \leq 0.05 \) were considered significant.

**RESULTS**

**Patient Disposition and Baseline Characteristics**

A total of 674 patients were registered, of whom 625 were evaluated (Figure 1). The most common reason for exclusion of registered patients from evaluation was protocol violation. The most common reason for discontinuation during the study was a subsequent change in insulin regimen.

The baseline characteristics of the patients were typical of Japanese patients with type 2 diabetes mellitus (Table 1).

Among the evaluated patients, the mean age was 63.3 years, the mean BMI was 24.52 kg/m² and there were more men (54.2%) than women (45.8%). Most patients had a prolonged history of diabetes and insulin treatment (mean durations of 16.15 and 7.17 years, respectively). Approximately 60% of patients were taking oral antidiabetic medications. Most patients (86.4%) had one or more complications of diabetes.

**Changes in Insulin Therapy**

Most (521 of 625; 83.4%) patients changed the type of insulin as part of the change in insulin regimen (Figure 2). Approximately 20% (126 of 625; 20.2%) of patients changed the type of device and approximately 30% (183 of 625; 29.3%) of patients changed the number of injections. Among patients who changed the number of injections, most (149 of 183; 81.4%) also changed the type of insulin.

Overall, the most common reason for changing insulin regimen was ‘poorly controlled glycemia’ (Table 2). This was the most common doctor-reported reason and the second most common patient-reported reason. Among patients, the most common reason for regimen change was ‘recommendation from the doctor’, which might have been related to poorly controlled glycemia, although this cannot be determined from the questionnaires. ‘Change of insulin preparation(s)’ was the second most common doctor-reported reason and the third most common patient-reported reason.

The three categories of insulin type were used with similar prevalence both before and after the change in insulin therapy (Table 3). Common timings of injections were before breakfast, lunch and dinner for rapid-acting insulin, and before breakfast and dinner for biphasic insulin. Regarding long-acting insulin, the most common timing of injection was bedtime. Biphasic insulin only (i.e. without an additional insulin type) was the most commonly used insulin both before and after the change in regimen (Table 4). Changes in insulin regimen were associated with a decrease in the proportion of patients using one type of insulin (from 64.5 to 55.4%) and an increase in the proportion of patients using two types of insulin (from 34.4 to 43.0%; Table 4).

The proportion of patients using each type of injection device did not change substantially after the change in insulin regimen. Disposable devices were the most common devices used both before (471 patients; 75.4%) and after (486 patients; 77.8%) the change in regimen. Cartridges (before change: 127 patients, 20.3%; after change: 94 patients, 15.0%) were also used. A small number of patients used both disposable devices and cartridges (before change: 43 patients, 6.9%). A few patients used syringes (before change: three patients, 0.5%; after change: two patients, 0.3%).

Most patients injected insulin two or three times a day both before and after the change in insulin regimen (Figure 3). However, the proportion of patients who injected insulin three or four times a day increased after the change in regimen.

**Quality of Life**

In the whole population, QOL did not worsen during the 12-week study. There was no statistically significant change in the ITR-QOL total score from baseline to week 12 (Table 5).
There was a small, but statistically significant, increase only in the daily activities subscale score. Ad hoc analysis by type of regimen changes (type of insulin, injection device and/or number of injections) in the ITR-QOL total score showed no statistically significant differences between subgroups in each type of change (Table 6). Statistically greater increases in the ITR-QOL total score from baseline to week 12 were observed in the subgroups of patients who changed type of insulin, who did not change type of injection device and who did not change the number of injections, whereas the ITR-QOL total score did not change in the subgroups of patients who did not change type of insulin, who changed type of injection device and who changed the number of injections.

Multiple linear regression analysis was also carried out, but none of the following variables were significantly associated with the change in the ITR-QOL total score: age, sex, BMI, duration of diabetes, baseline HbA1c level, the number of injections per day before regimen change, type of insulin before regimen change and device before regimen change (data not shown).

The ‘perceived frequency of hyperglycemia’ DTSQ subscale score (mean ± SD) decreased significantly at 12 weeks from baseline (baseline: 3.4 ± 1.6; week 12: 3.0 ± 1.7; n = 573; P ≤ 0.001), in accordance with improved glycemic control. The ‘treatment satisfaction’ DTSQ subscale mean improved numerically, but was not statistically significant at week 12 (baseline: 24.8 ± 6.4; week 12: 25.4 ± 6.4; n = 552). There was little change in the ‘perceived frequency of hypoglycemia’ (baseline: 1.7 ± 1.5; week 12: 1.8 ± 1.5; n = 571; P = 0.106) DTSQ subscale score.

**Plasma HbA1c Levels**

Plasma HbA1c levels decreased significantly (mean change = -0.37 ± 0.97%, n = 606, P < 0.001) from 8.21 ± 1.47% (n = 618) at baseline to 7.85 ± 1.31% (n = 610) at week 12.

---

**Table 2 | Reasons for change in insulin therapy**

| Reason                              | Doctor-reported n (%) | Patient-reported n (%) | Agreement rate |
|-------------------------------------|-----------------------|------------------------|----------------|
| Poorly controlled glycemia          | 388 (62.1%)           | 313 (50.1%)            | 0.75           |
| Change of insulin preparation(s)    | 179 (28.6%)           | 106 (17.0%)            | 0.70           |
| Dissatisfaction with device         | 69 (11.0%)            | 56 (9.0%)              | 0.85           |
| Concern about hypoglycemia          | 53 (8.5%)             | 62 (9.9%)              | 0.86           |
| Dissatisfaction with number of doses| 32 (5.1%)             | 31 (5.0%)              | 0.94           |
| User-friendliness                   | 20 (3.2%)             | 22 (3.5%)              | 0.95           |
| Patient request (for doctors) or    | 17 (2.7%)             | 407 (65.1%)            | 0.32           |
| doctor recommendation (for patients)|                      |                        |                |
| Concern about safety other than     | 3 (0.5%)              | 17 (2.7%)              | 0.97           |
| hypoglycemia                        |                       |                        |                |
| Other                               | 83 (13.3%)            | 54 (8.6%)              | 0.84           |
| No answer                           | 2 (0.3%)              | 31 (5.0%)              | NA             |

NA, not applicable.

**Figure 2 | Overlap of changes in insulin type, device and number of injections among patients with type 2 diabetes mellitus (n = 625).**
Subgroup analysis based on the type of changes in plasma HbA1c levels showed statistically significantly greater decreases in plasma HbA1c levels in patients who changed the type of insulin or the number of injections compared with patients who did not make these changes (Table 7).

Multiple linear regression analysis identified a statistically significant association between the change in plasma HbA1c level and the baseline HbA1c level, baseline BMI, and the number of insulin injections before the regimen change (Table 8). Independent variables including age, sex, duration of diabetes, type of insulin before regimen change and device before regimen change were not significant. The decrease in plasma HbA1c level was greater in patients with higher baseline HbA1c levels compared with patients with lower HbA1c levels, in patients with BMI <25 kg/m² compared with patients with BMI ≥25 kg/m² and in patients with two or more insulin injections per day before the change in regimen compared with patients with one injection before the change. These associations were confirmed by backward, step-down regression analysis. However, these variables only accounted for 27% of the variance in the change in plasma HbA1c levels.

There was a small, but statistically significant, increase in the total daily dose of insulin (baseline: 30.7 ± 21.8 IU; week 12: 31.5 ± 20.1 IU; change = 0.8 ± 9.0 IU; n = 620; P = 0.023)

---

**Table 3** | Changes in insulin type and injection time before and during the 12-week study

| Category of insulin | Type of insulin | Injection time | Before change | After change* | Week 12 |
|---------------------|----------------|----------------|---------------|--------------|--------|
| Rapid-acting        | Any            | n (%)          | n (625)       | n (625)      | n (622) |
|                     | Rapid-acting insulin | Before breakfast | 255 (40.8%)   | 268 (42.9%)   | 265 (42.6%) |
|                     | Ultra-rapid-acting analog | Before lunch    | 228 (36.5%)   | 235 (37.6%)   | 233 (37.5%) |
| Biphasic            | Any            | n (%)          | n (625)       | n (625)      | n (622) |
|                     | Biphasic insulin | Before breakfast | 229 (36.6%)   | 235 (37.6%)   | 232 (37.3%) |
|                     | Biphasic analog | Before dinner   | 185 (29.6%)   | 205 (32.8%)   | 203 (32.6%) |
|                     | Bedtime        | 0 (0.0%)       | 0 (0.0%)      | 0 (0.0%)     |
| Long-acting         | Any            | n (%)          | n (625)       | n (625)      | n (622) |
|                     | Intermediate-acting insulin | Before breakfast | 268 (42.9%)   | 314 (50.2%)   | 313 (50.3%) |
|                     | Intermediate-acting analog | Before lunch    | 63 (10.1%)    | 120 (19.2%)   | 121 (19.5%) |
|                     | Bedtime        | 2 (0.3%)       | 1 (0.2%)      | 1 (0.2%)     |

*Immediately after change in insulin therapy (i.e. baseline).

**Table 4** | Changes in insulin type combinations before and during the 12-week study

| Combination            | Before change | After change* | Week 12 |
|------------------------|---------------|---------------|--------|
| n (%)                  | n (625)       | n (625)       | n (622) |

| No insulin used        | 0 (0.0%)      | 0 (0.0%)      | 2 (0.3%) |
| Rapid-acting only      | 49 (7.8%)     | 21 (3.4%)     | 21 (3.4%) |
| Biphasic only          | 235 (37.6%)   | 271 (43.4%)   | 271 (43.6%) |
| Long-acting only       | 119 (19.0%)   | 54 (8.6%)     | 53 (8.5%) |
| Rapid-acting + biphasic| 63 (10.1%)    | 51 (8.2%)     | 51 (8.2%) |
| Rapid-acting + long-acting | 136 (21.8%) | 186 (29.8%) | 183 (29.4%) |
| Biphasic + long-acting | 16 (2.6%)     | 32 (5.1%)     | 31 (5.0%) |
| Rapid-acting + biphasic | 7 (1.1%)     | 10 (1.6%)     | 10 (1.6%) |

*Immediately after change in insulin therapy (i.e. baseline).

---

**Figure 3** | Number of insulin injections per day among patients with type 2 diabetes mellitus before (white columns) and after (black columns) changing insulin regimen (n = 625).
during the study; however, the increase was not considered clinically significant.

**Patient-Reported Treatment Adherence**

The change in insulin regimen was not associated with any apparent change in patient-reported treatment adherence. Most patients reported adhering to treatment always or often at all injection times both before and after the change in insulin regimen.

**Concomitant Oral Antidiabetic Medication**

The proportion of patients who were taking concomitant oral antidiabetic medication decreased slightly after the change in insulin regimen (before change: \(n = 366\); 58.6%; after change: \(n = 347\); 55.5%) and was maintained at week 12 (\(n = 348\); 55.7%).

**DISCUSSION**

The psychological barriers to initiating or intensifying insulin therapy are well known and include a fear of reduced QOL. Although patients are generally more receptive to changing insulin regimen than to initiating insulin, some psychological barriers still exist, including perceived effects on daily activities, the burden of an increased number of injections and worry about weight gain. Most studies of QOL in relation to insulin treatment have focused on comparisons between human insulin or insulin analog initiation, rather than the effect of changing insulin regimen. However, because of the progressive nature of type 2 diabetes mellitus, most patients will eventually need intensification of insulin therapy to maintain glycemic control. The present study is the first to examine the effects of a range of insulin regimen changes on these parameters in a clinical practice setting, and contributes

---

**Table 5** | Insulin therapy-related quality of life subscale and total scores during the 12-week study

| Subscale (range of possible scores) | Score | P-value* |
|-------------------------------------|-------|----------|
|                                     | Mean (SD) |          |
| **Baseline**                        |        |          |
| Social activities (5-25 points)     | 22.0 (3.7) | 0.12 (2.99) | 0.341 |
| Physical functioning (4-20 points) | 173 (2.5) | 0.04 (2.17) | 0.672 |
| Daily activities (3-15 points)      | 127 (2.3) | 0.18 (2.08) | 0.038 |
| Feeling about insulin treatment (11-55 points) | 446 (9.0) | 0.54 (7.06) | 0.073 |
| **Total score** (23-115 points)     | 97.0 (15.2) | 0.86 (11.25) | 0.082 |

*One-sample t-test. SD, standard deviation.

**Table 6** | Subgroup analysis of changes in the Insulin Therapy-Related Quality of Life total score during the 12-week study

| Insulin therapy change | ITR-QOL total score | Within group | Difference between groups† (95% CI) | Between group |
|------------------------|---------------------|--------------|-----------------------------------|---------------|
|                        | Mean (SD)           | Mean (SD)    | Change from baseline               | P-value§      |
|                        | Baseline Week 12    |              |                                   |               |
| **Type of insulin**    |                     |              |                                   |               |
| Not changed            | 97.3 (13.5)         | 97.3 (14.8)  | −0.18 (10.30)                     | 0.848         |
| Changed                | 96.9 (15.7)         | 97.9 (15.8)  | 1.18 (11.52)                      | 0.042         |
| **Type of injection device** |                |              |                                   |               |
| Not changed            | 97.1 (15.4)         | 97.9 (15.9)  | 1.19 (11.37)                      | 0.034         |
| Changed                | 96.5 (14.5)         | 97.2 (14.6)  | −0.12 (10.70)                     | 0.685         |
| **No. injections**     |                     |              |                                   |               |
| Not changed            | 96.7 (15.5)         | 98.1 (15.6)  | 1.25 (10.77)                      | 0.027         |
| Changed                | 97.7 (14.6)         | 97.0 (15.6)  | −0.10 (12.33)                     | 0.921         |

*One-sample t-test. †Mean change from baseline in the ‘Changed’ group minus mean change from baseline in the ‘Not changed’ group. §Two-sample t-test. CI, confidence interval; ITR-QOL, Insulin Therapy-Related Quality of Life; SD, standard deviation.
In the present large observational study, changes of insulin therapy improved glycemic control in Japanese patients with type 2 diabetes mellitus without adversely affecting QOL. Patients enrolled in the present study were relatively established diabetic patients with more than 16 years’ history of illness and more than 7 years of insulin treatment on average. Therefore, it was expected that the changes in insulin therapy were at the level of ‘modification’. In fact, the majority of changes in insulin therapy were changes in the type of insulin, and only approximately 20 and 30% of patients changed the device and the number of injections, respectively. This would be the primary reason why the changes in insulin therapy did not significantly affect patients’ QOL.

Table 7: Subgroup analysis of changes in plasma glycated hemoglobin levels during the 12-week study

| Insulin therapy change | HbA1c Mean% (SD)          | Within group P-value* | Difference between groups† (95% CI) | Between group P-value§ |
|-----------------------|---------------------------|-----------------------|-------------------------------------|-------------------------|
|                       | Baseline Week 12 Change from baseline |                       |                                     |                         |
| Type of insulin       |                           |                       |                                     |                         |
| Not changed           | 8.11 (1.56) n = 135       | 7.87 (1.35) n = 135   | −0.21 (0.80) 0.003                 |                         |
| Changed               | 8.24 (1.44) n = 483       | 7.85 (1.29) n = 478   | −0.41 (1.01) <0.001                | −0.20 (−0.39, −0.01) 0.035 |
| Type of injection device |                         |                       |                                     |                         |
| Not changed           | 8.24 (1.44) n = 493       | 7.87 (1.33) n = 487   | −0.38 (1.00) <0.001                |                         |
| Changed               | 8.11 (1.55) n = 125       | 7.80 (1.21) n = 123   | −0.31 (0.86) <0.001                |                         |
| No. injections        |                           |                       |                                     |                         |
| Not changed           | 8.01 (1.35) n = 438       | 7.77 (1.33) n = 431   | −0.25 (0.84) <0.001                |                         |
| Changed               | 8.72 (1.62) n = 180       | 8.06 (1.22) n = 179   | −0.66 (1.18) <0.001                | −0.42 (−0.58, −0.25) <0.001 |

*One-sample t-test. †Mean change from baseline in the ‘Changed’ group minus mean change from baseline in the ‘Not changed’ group. §Two-sample t-test. CI; confidence interval; HbA1c; glycated hemoglobin; SD; standard deviation.

In insulin therapy. Thus, doctors can reassure patients that modifying their insulin therapy is unlikely to detract from their QOL.

Interestingly, ‘doctor recommendation’ was the main patient-reported reason for changing insulin regimen, suggesting that patients might not fully understand the clinical reasons for changing their regimen. Similar findings were reported in a substudy of the Treating to Target in Type 2 Diabetes trial, in which patients who required intensification of insulin therapy were willing to do so when recommended by their doctor. Because patients who understand the reasons for changes in therapy are more motivated to adhere to treatment, doctors should openly discuss potential changes in insulin regimen to ensure patients are actively involved in the decision.

The results of the present study are strengthened by the large number of patients from 68 medical centers. The present study provides an important ‘snapshot’ of the current pattern of insulin use among Japanese patients with type 2 diabetes mellitus. The patients in the present study used a wide range of insulin types, and no single type predominated. In Japan, biphasic insulin was used as frequently as rapid-acting and long-acting insulin. This is in contrast to Western countries, where guidelines from the American Diabetes Association and the European Association for the Study of Diabetes recommend long-acting basal insulin for insulin initiation. This difference in insulin type might be because intrinsic insulin secretion after meals is more impaired in patients from Japan than in patients from Western countries.
The present study had several limitations. As expected in an observational study, there was considerable heterogeneity in both the study population and insulin regimens. However, the intention of the study was to examine ‘real-life’ clinical practice in a broad range of patients with type 2 diabetes mellitus in Japan. Because the study did not include a control group, the observed improvement in glycemic control cannot be ascribed directly to the change in insulin regimen, as other factors (e.g. changes in lifestyle) might have contributed. One limitation of the QOL scales we used was the difficulty in detecting improvements if the initial ratings were relatively high (i.e. ‘ceiling effect’). We also cannot exclude the possibility that participation in the study itself might have affected patients’ perception of QOL. Finally, because of the limited duration of the study, we do not know how long QOL and glycemic control are maintained during treatment with the new insulin regimen or whether they are maintained after subsequent regimen changes.

In conclusion, it was suggested that changes in insulin regimen might improve glycemic control in patients with type 2 diabetes mellitus without detracting from QOL. The range of insulin types currently available in Japan allows doctors’ flexibility in tailoring insulin therapy to optimize both the clinical and QOL needs of individual patients. This is the first publication for the INSIGHTs observational study focusing on the whole study population. Further subgroup analysis by

| Variables | Full regression model | Step-down regression model |
|-----------|----------------------|---------------------------|
|           | Regression coefficient (95% CL) | P-value | Regression coefficient (95% CL) | P-value |
| Intercept | 1.63 (1.09, 2.17) | <0.001 | 1.85 (1.42, 2.28) | <0.001 |
| Age       | Reference            | – | Reference            | – |
| ≥65 years | 0.02 (−0.13, 0.16) | 0.815 | 0.20 (0.06, 0.34) | 0.006 |
| Sex       | Reference            | – | Reference            | – |
| Female    | 0.07 (−0.07, 0.21) | 0.310 | 0.19 (−0.64, 1.02) | 0.653 |
| BMI       | 0.051                | 0.022 | 0.640                | 0.19 |
| <25 kg/m² | Reference            | – | Reference            | – |
| ≥25 kg/m² | 0.18 (0.03, 0.32) | 0.016 | 0.20 (0.06, 0.34) | 0.006 |
| Unknown   | 0.20 (−0.64, 1.05) | 0.634 | 0.19 (−0.64, 1.02) | 0.653 |
| Duration of diabetes | 0.728 | | |
| <15 years | Reference            | – | Reference            | – |
| ≥15 years | 0.06 (−0.21, 0.09) | 0.449 | 0.33 (−0.37, −0.28) | <0.001 |
| Unknown   | 0.07 (−0.34, 0.21) | 0.634 | 0.33 (−0.37, −0.28) | <0.001 |
| Baseline plasma HbA1c level | −0.33 (−0.38, −0.28) | <0.001 | −0.33 (−0.37, −0.28) | <0.001 |
| No. injections per day before regimen change | 0.09 | 0.069 | 0.038 |
| 1         | Reference            | – | Reference            | – |
| 2         | 0.23 (−0.02, 0.49) | 0.073 | 0.25 (0.03, 0.47) | 0.023 |
| 3         | 0.41 (0.09, 0.73) | 0.01 | 0.33 (0.10, 0.55) | 0.004 |
| 4         | 0.51 (0.09, 0.93) | 0.01 | 0.27 (0.02, 0.53) | 0.035 |
| Type of insulin before regimen change | 0.368 | | |
| Rapid-acting only | Reference            | – | Reference            | – |
| Biphasic  | 0.30 (0.01, 0.59) | 0.044 | 0.25 (0.03, 0.47) | 0.023 |
| Long-acting only | 0.24 (−0.12, 0.59) | 0.188 | 0.33 (0.10, 0.55) | 0.004 |
| Rapid-acting + biphasic | 0.17 (−0.15, 0.50) | 0.292 | 0.27 (0.02, 0.53) | 0.035 |
| Biphasic + long-acting | 0.17 (−0.34, 0.67) | 0.519 | 0.27 (0.02, 0.53) | 0.035 |
| Rapid + long-acting | 0.05 (−0.65, 0.75) | 0.887 | 0.27 (0.02, 0.53) | 0.035 |
| Device before change | Device before change | 0.130 | | |
| Disposable | Reference            | – | Reference            | – |
| Cartridge  | 0.01 (−0.17, 0.19) | 0.907 | 0.27 (0.02, 0.53) | 0.035 |
| Syringe   | −0.88 (−1.85, 0.09) | 0.076 | 0.27 (0.02, 0.53) | 0.035 |
| Disposable + cartridge | 0.31 (−0.08, 0.69) | 0.115 | 0.27 (0.02, 0.53) | 0.035 |
| Coefficient of determination (r²) | 0.270 | 0.0253 | | |

BMI, body mass index; CL, confidence limit; HbA1c, glycated hemoglobin.
various aspects might provide additional information regarding glycemic control and patients’ QOL.

ACKNOWLEDGEMENTS
This study was funded by Eli Lilly Japan K.K. In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, the sponsor of this study did not impose any impediment, directly or indirectly, on the publication of the study results. The authors wish to acknowledge Ikuo Tsujii and Shiko Takamiya for their contributions to interpretation of data and critical suggestions for improvement of this manuscript. Medical writing services were provided by Rebecca Lew, PhD, and Serina Stretton, PhD, of ProScribe Medical Communications, and were funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). Eli Lilly Japan K.K. was involved in the study design, data collection, data analysis and preparation of the manuscript. M Taketsuna, M Takeuchi and T Imaoka are employees of Eli Lilly Japan K.K. H Ishii and H Jinnouchi consult for Eli Lilly Japan K.K. Y Terauchi has been a member of advisory boards, and has received consulting fees and unrestricted research grants from Eli Lilly Japan K.K., Novo Nordisk and Sanofi.

REFERENCES
1. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–117.
2. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl. 2): B21–B29.
3. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 2008; 359: 1577–1589.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
5. Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabetes Metab Res Rev 2009; 25(Suppl. 1): S4–S10.
6. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15: 205–218.
7. Zhang X, Norris SL, Chowdhury FM, et al. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. Med Care 2007; 45: 820–834.
8. Vijan S, Hayward R, Ronis D, et al. Brief report: the burden of diabetes therapy. J Gen Intern Med 2005; 20: 479–482.
9. Bradley C, Gilbride CJ. Improving treatment satisfaction and other patient-reported outcomes in people with type 2 diabetes: the role of once-daily insulin glargine. Diabetes Obes Metab 2008; 10(Suppl. 2): 50–65.
10. Bradley C, Plowright R, Stewart J, et al. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. Health Qual Life Outcomes 2007; 5: 57.
11. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073–1084.
12. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; (2): CD005613.
13. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165: 1337–1344.
14. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006; (2): CD003287.
15. Ishii H, Iwase M, Seino H, et al. Assessment of quality of life in patients with type 2 diabetes mellitus before and after starting biphasic insulin aspart 30 (BIAsp 30) therapy: IMPROVE study in Japan. Curr Med Res Opin 2011; 27: 643–650.
16. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005; 28: 1568–1573.
17. Ishii H, Anderson JH Jr, Yamamura A, et al. Improvement of glycemic control and quality-of-life by insulin lispro therapy: assessing benefits by ITR-QOL questionnaires. Diabetes Res Clin Pract 2008; 81: 169–178.
18. Ishii H, Yamamoto T, Ohashi Y. Development of insulin therapy related quality-of-life measure (ITR-QOL). J Jpn Diabetes Soc 2001; 44: 9–15 (Japanese).
19. Japan Pharmaceutical Manufacturers Association. Postmarketing Surveillance of Drugs. Pharmaceutical Administration and Regulations in Japan. (Cited March 2012). Available at URL: http://www.jpma.or.jp/english/parj/1203.html.
20. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212–228.
21. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39–40.
22. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In: Bradley C (ed). Handbook of Psychology and
Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Harwood Academic Publishers, Chur, Switzerland, 1994; 111–132.

23. Ishii H, Bradley C, Riazi A, et al. The Japanese version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ): translation and clinical evaluation. *J Clin Exp Med* 2000; 192: 809–814 (Japanese).

24. Kobayashi M, Yamazaki K, Hirao K, et al. The status of diabetes control and antidiabetic drug therapy in Japan–A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). *Diabetes Res Clin Pract* 2006; 73: 198–204.

25. Kunt T, Snoek FJ. Barriers to insulin initiation and intensification and how to overcome them. *Int J Clin Pract* 2009; 63: 6–10.

26. Jenkins N, Hallowell N, Farmer AJ, et al. Participants’ experiences of intensifying insulin therapy during the Treating to Target in Type 2 Diabetes (4-T) trial: qualitative interview study. *Diabet Med* 2011; 28: 543–548.

27. Delamater AM. Improving patient adherence. *Clin. Diabetes* 2006; 24: 71–77.

28. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2009; 32: 193–203.

29. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. *Diabetes Res Clin Pract* 2004; 66: 537–543.

30. Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. *Diabetes Metab Res Rev* 2011; 27: 79–84.